Search

Serbia Mutual Evaluation AML/CFT/CPF Measures Report

FATF published its 2025 Mutual Evaluation Report assessing Serbia's Anti-Money Laundering and Counter-Terrorist Financing/Proliferation (AML/CFT/CPF) framework. The report evaluates Serbia's compliance with FATF Recommendations and the effectiveness of its AML/CFT/CPF measures across 40 recommendations.

Updated Opioid Dependence Treatment and Overdose Prevention Guidelines

WHO announced updates to guidelines for opioid dependence treatment and overdose prevention, including new conditional recommendations for long-acting injectable buprenorphine alongside continued strong recommendations for methadone and oral buprenorphine. The full guidelines are expected later in 2026 or early 2027. Currently, fewer than 10% of approximately 64 million people worldwide with drug use disorders receive treatment.

ISO 20022 CBPR+ Address Structuring Deadline November 2026

SWIFT announced that the CBPR+ ISO 20022 migration achieved 97% adoption as of November 2025. A new requirement mandates removal of unstructured postal addresses from CBPR+ payment messages by November 2026. After this date, only fully structured or hybrid postal addresses will be accepted; payments with non-compliant addresses may be rejected or delayed by PSPs. Standards Release 2026 Usage Guidelines were published February 20, 2026.

Georgia Local Democracy Jeopardized - Congress Report

The Congress of Local and Regional Authorities of the Council of Europe issued a report finding local democracy in Georgia to be in jeopardy, citing rapid democratic backsliding, high polarisation, one-party rule over local authorities, and lack of follow-up on past recommendations. The Congress debated findings from a fact-finding visit conducted September 24-25, 2025, and deplored irregularities in the October 4, 2025 local elections including widespread boycotts, electoral law changes, and intimidation of opposition voices.

COVID-19 Vaccine Antigen Composition Data Request for May 2026

WHO's Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) has issued updated guidance requesting vaccine manufacturers submit immunological, virological, and vaccine effectiveness data ahead of the May 2026 decision-making meeting. The statement updates previous September 2025 guidance and specifies key antisera and antigens of interest including JN.1, KP.2, XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 variants. Manufacturers should submit both pre- and post-vaccination antisera analysis for neutralization testing.